Education
About Us
Working with TipRanks
Follow Us
PhoenixBio Co., Ltd. (JP:6190)
:6190
6190 Stock Chart & Stats
¥484.00
¥9.00(2.79%)
At close: 4:00 PM EST
¥484.00
¥9.00(2.79%)
Day’s Range― - ―
52-Week Range¥252.00 - ¥809.00
Previous CloseN/A
Volume3.50K
Average Volume (3M)360.67K
Market Cap
¥1.90B
Enterprise Value¥1.35B
Total Cash (Recent Filing)¥1.04B
Total Debt (Recent Filing)¥503.59M
Price to Earnings (P/E)―
Beta0.48
Next Earnings
May 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)19.91
Shares Outstanding4,076,933
10 Day Avg. Volume91,460
30 Day Avg. Volume360,670
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.09
Price to Sales (P/S)0.97
P/FCF Ratio-15.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Humanized‑mouse PlatformOwning a specialized PXB humanized‑mouse platform creates a durable, high‑barrier business model. It supports recurring revenue from model sales, licensing and fee‑for‑service studies for drug metabolism and toxicity, anchoring long‑term customer relationships and sticky demand.
Healthy Equity Ratio / Moderate LeverageA stable equity base and moderate debt provide financial flexibility during R&D cycles and negative cash flow periods. Lower reliance on debt reduces refinancing risk and preserves the company’s ability to fund ongoing platform operations and selective investments over months ahead.
Historically Strong Gross MarginsSustained strong gross margins indicate the platform and products command pricing power and efficient direct costs. Even with revenue variability, margin strength supports unit economics for service contracts and product sales, improving potential profitability as volumes normalize.
Bears Say
Negative Operating Cash FlowPersistent negative operating and free cash flow constrains the firm’s ability to self‑fund R&D, capacity expansion, or absorb cyclical revenue dips. Over a 2–6 month horizon this raises reliance on external financing and limits strategic optionality.
Ongoing Negative ProfitabilityNegative operating and net margins reflect structural profitability challenges. Without margin recovery, the business struggles to generate earnings despite a strong platform, reducing reinvestment capacity and making long‑term commercial scale harder to achieve.
Declining Revenues And Asset BaseFalling revenues coupled with a shrinking asset base suggest contraction in scale or utilization. This undermines fixed‑cost absorption and may weaken competitive positioning, limiting the company’s ability to capitalize on its platform without restoring growth.
6190 FAQ
What was PhoenixBio Co., Ltd.’s price range in the past 12 months?
PhoenixBio Co., Ltd. lowest stock price was ¥252.00 and its highest was ¥809.00 in the past 12 months.
What is PhoenixBio Co., Ltd.’s market cap?
PhoenixBio Co., Ltd.’s market cap is ¥1.90B.
When is PhoenixBio Co., Ltd.’s upcoming earnings report date?
PhoenixBio Co., Ltd.’s upcoming earnings report date is May 20, 2026 which is in 92 days.
How were PhoenixBio Co., Ltd.’s earnings last quarter?
PhoenixBio Co., Ltd. released its earnings results on Feb 13, 2026. The company reported ¥19.91 earnings per share for the quarter, beating the consensus estimate of N/A by ¥19.91.
Is PhoenixBio Co., Ltd. overvalued?
According to Wall Street analysts PhoenixBio Co., Ltd.’s price is currently Overvalued.
Does PhoenixBio Co., Ltd. pay dividends?
PhoenixBio Co., Ltd. does not currently pay dividends.
What is PhoenixBio Co., Ltd.’s EPS estimate?
PhoenixBio Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PhoenixBio Co., Ltd. have?
PhoenixBio Co., Ltd. has 4,076,933 shares outstanding.
What happened to PhoenixBio Co., Ltd.’s price movement after its last earnings report?
PhoenixBio Co., Ltd. reported an EPS of ¥19.91 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -3.112%.
Which hedge fund is a major shareholder of PhoenixBio Co., Ltd.?
Currently, no hedge funds are holding shares in JP:6190
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PhoenixBio Co., Ltd.
PhoenixBio Co., Ltd. provides contract study services for drug discovery and development primarily in Japan. The company uses PXB-mouse, a chimeric mouse with a humanized liver for use in drug development experiments; and in vitro studies using fresh human hepatocytes taken from PXB-cells. The chimeric mouse model with a humanized liver is used for in vivo studies in gene therapeutics, NASH/NAFLD drug development programs, anti-viral therapeutic tests, DMPK/toxicity studies, and custom transplantations. The company was founded in 2002 and is headquartered in Higashihiroshima, Japan.
Technical Analysis
Trans Genic Inc.
―
Soiken Holdings Inc.
―
Ribomic, Inc.
―
BrightPath Biotherapeutics Co.Ltd.
―
FunPep Company Limited
―